The rationale behind the new Alzheimer’s disease conceptualization: lessons learned during the last decades

Manuscript Number: 


Juan D. Gispert, Carolina Minguillon, José-Luis Molinuevo, Lorena Rami


Juan D. Gispert

  • Consulting Fees:
    I have received consulting fees from IRAB (Institut de Radiofarmàcia Aplicada de Barcelona) (< 10000 €)
    Lecture Fees:
    I have received lecture fees from Philips Healthcare (< 1000 €)

Carolina Minguillon

  • Nothing to Disclose

José-Luis Molinuevo

  • Consulting Fees:
    Scientific Consultancy for: Roche Pharma,Lundbeck, Merz, Biogen, Roche Pharma, IBL, Raman Health, Roche Diagnostics, Lilly, Axovant Trial board member for: Genentech, Novartis None of these activities are related to the contents of this manuscript

Lorena Rami

  • Nothing to Disclose